Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer.
about
Taxane-containing regimens for metastatic breast cancerSingle agent versus combination chemotherapy for metastatic breast cancerTaxanes for adjuvant treatment of early breast cancerTaxane containing regimens for metastatic breast cancerActivity of the kinesin spindle protein inhibitor ispinesib (SB-715992) in models of breast cancerHow to calculate the dose of chemotherapyA structured review of health utility measures and elicitation in advanced/metastatic breast cancerA phase II study of sequential 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel in advanced breast cancer (Protocol PV BC 97/01)Model-based meta-analysis for quantifying Paclitaxel dose response in cancer patients.Evaluating health-related quality-of-life therapeutic effectiveness in a clinical trial with extensive nonignorable missing data and heterogeneous response: results from a phase III randomized trial of gemcitabine plus paclitaxel versus paclitaxel mRisk of subsequent dementia diagnoses does not vary by types of adjuvant chemotherapy in older women with breast cancer.Recent advances in the systemic therapy of breast cancer.Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer.Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective.The role of taxanes in the management of gastroesphageal cancerThe role of taxanes in the treatment of breast cancer.A systematic review of taxane-containing regimens for metastatic breast cancer.Neoadjuvant systemic therapy for breast cancer: an overview and review of recent clinical trials.A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101.Progression-free survival as a surrogate endpoint in advanced breast cancerConcurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197Ixabepilone for the treatment of taxane-refractory breast cancer.Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cellsInternational guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy.Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer.Eribulin -- a review of preclinical and clinical studies.Quality of life assessments in advanced breast cancer: should there be more consistency?Taxane-induced arthralgia and myalgia: A literature review.Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review.Taxane therapy for early stage breast cancer.Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma.Weekly taxanes--a leap forward or a minute progress?Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer.Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis.
P2860
Q24187214-A4242993-EADF-4C23-BD75-DFDB8F218E11Q24241459-D187FF38-2819-40E8-BD39-53A203AAAC56Q24242987-C1E9FC65-6BC0-432D-8244-85F569E6B7EDQ24246978-8AAC8F85-46FA-4B2C-924B-CBC9D34E6AB9Q24615262-726A21A6-8707-4099-A5F3-8E5B042788DFQ24642872-EEF3CF8D-F7B5-4F77-9119-8051FC855B97Q28067255-D218908A-BB56-4322-BE6C-D5C170E3F055Q28344321-D5EF7EA4-393F-4BA8-84A5-ECC7F303FC03Q33749066-71B8EF4D-581B-4DA4-BA97-D8DDA2978875Q34020507-15B4B756-4422-406C-ACCD-6E0D521044FDQ34815323-4B94E7E0-F953-4A85-A577-49357BABEED8Q35052282-270C6C7C-AA9C-4E56-B6DC-92A1BB0F4BA8Q35599769-F3CDF31B-516A-4960-BB8D-626E013EC554Q35617654-00BBCABF-F856-4BFB-8356-7F3A8A4F5497Q36097240-C7A6EC25-4AB0-4595-A119-2E7D0A9D4A15Q36163956-83E46480-C0D7-4C4D-8631-AFAF58563D2FQ36211570-6F432ED2-7DE5-4C3E-9B2C-F3940804BE6AQ36221963-6950DD40-7FA9-46ED-8474-96FC483F832AQ36243420-59EDD4E0-DBB6-4681-A1B1-F073566F0A50Q36552307-113FA3FB-59B1-4FB7-869D-0D47651EE143Q37125089-94B3F611-C95F-4188-B009-F125150BBCDCQ37179381-5C620C83-4810-4B16-B1E3-91D547697B5DQ37205578-3BF9084B-A975-4DA9-B3ED-BED786C2F41AQ37329165-0DF7064D-75F9-4A6A-8346-3ADA5503D593Q37344525-A7C2FF96-F7E2-4F2F-8E74-76C735132B01Q37637936-FBF94997-327B-4F16-A9FE-F4E8917D7F31Q38016575-D483A084-7C7B-46B1-9640-852BE65AF992Q38711952-6A2BA4CF-0867-4EBB-9427-3DB8E01E5FB9Q38726616-54CFBF44-2D50-4F91-8B7B-DA47BC59EDFFQ43267052-D9171073-384E-4E7E-848C-19001059141CQ43869754-1C44D409-CC0C-4F75-9010-10F80E310229Q44833158-364F489A-1C06-4873-9B6F-3DDE97D63E0CQ46226343-C1B8DB88-DDA0-4DF6-88A2-865D8F5EE569Q48615482-C1A066BC-F841-43D3-ADB4-F88A107DA74F
P2860
Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer.
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Initial paclitaxel improves ou ...... ated metastatic breast cancer.
@ast
Initial paclitaxel improves ou ...... ated metastatic breast cancer.
@en
Initial paclitaxel improves ou ...... ated metastatic breast cancer.
@nl
type
label
Initial paclitaxel improves ou ...... ated metastatic breast cancer.
@ast
Initial paclitaxel improves ou ...... ated metastatic breast cancer.
@en
Initial paclitaxel improves ou ...... ated metastatic breast cancer.
@nl
prefLabel
Initial paclitaxel improves ou ...... ated metastatic breast cancer.
@ast
Initial paclitaxel improves ou ...... ated metastatic breast cancer.
@en
Initial paclitaxel improves ou ...... ated metastatic breast cancer.
@nl
P2093
P1476
Initial paclitaxel improves ou ...... ated metastatic breast cancer.
@en
P2093
D Goldstein
J F Bishop
P304
P356
10.1200/JCO.1999.17.8.2355
P407
P577
1999-08-01T00:00:00Z